Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test clues could make antifungal dosing safer for transplant patients

NCT ID NCT07716878

Knowledge-focused Sponsor: Zhibin Xu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study looks back at medical records of transplant recipients (lung, kidney, liver, or bone marrow) who received the antifungal drug isavuconazole. Researchers want to understand why blood levels of the drug vary so much between patients and whether higher levels are linked to liver problems. By analyzing routine blood test results, they hope to find ways to personalize dosing and improve safety. The study does not test a new treatment but gathers information from standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
isavuconazole
What this could lead to
If successful, this study could help doctors personalize isavuconazole dosing for transplant patients, reducing the risk of liver side effects while effectively preventing or treating fungal infections.
What could go wrong
This is a small, single-center observational study, not a controlled trial. Results may not apply to other hospitals or patient groups, and the findings are only associations, not proof of cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

110 people

The number who actually took part.

Started

Jan 2024

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive solid organ (lung, kidney, liver) and hematopoietic stem cell transplant recipients who received isavuconazole and underwent routine therapeutic drug monitoring at a single tertiary-care hospital in China between January 2024 and April 2026. A total of 110 recipients were included (89 lung, 6 kidney, 2 liver, and 13 hematopoietic stem cell transplant), contributing 427 trough concentration measurements.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Recipients of solid organ transplantation (lung, kidney, or liver) or hematopoietic stem cell transplantation * Received isavuconazole for prophylaxis or treatment of invasive fungal infection during the study period, with traceable prescription and administration records * Isavuconazole treatment duration of at least 7 days and at least one measured plasma isavuconazole trough concentration * Adequate follow-up information to assess the main study variables Exclusion Criteria: * No available plasma isavuconazole trough concentration * Incomplete key clinical or dosing records precluding analysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematopoietic stem cell transplantation (HSCT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Invasive Fungal Infections systemic mycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematopoietic stem cell transplantation (HSCT) Invasive fungal infections Kidney transplantation Liver transplantation (LT) Lung transplantation

Contacts and locations

Locations

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.